A Randomized, Double-Blind (Sponsor Unblinded), Placebo-Controlled, Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH4524184 in HIV-1 Infected Treatment Naïve Adults
This study, called a Phase II trial, is looking into a new medication named VH4524184 for adults living with HIV-1 who have not yet received any HIV treatment. The main goal is to find out how effectively this new medicine reduces the amount of HIV in the blood over 10 days. We will also be carefully checking for any side effects and how safe the medicine is. Participants will receive either the new medicine or a dummy pill (placebo), and neither they nor their doctors will know which one they are taking at the time. This helps us to get clear results. Researchers will also be studying how the body absorbs and processes the medicine. This is an important step in developing new treatments for HIV.
At a glance
What is this study about?
This study is a Phase II clinical trial, which means it's an early but important step in developing a new medicine. We're investigating a new drug called VH4524184, which is designed to fight the Human Immunodeficiency Virus (HIV). Specifically, we're looking at adults who have been diagnosed with HIV-1 but have not yet started any medication for it. The main purpose of this study is to see how well this new drug can reduce the amount of HIV in a person's blood over a short period of 10 days. This is an indicator of how effective the drug might be in controlling the virus.
Beyond just its effectiveness, we also want to understand the safety of VH4524184. Like all medicines, new drugs can have side effects. We'll be closely monitoring participants for any unwanted effects and how their bodies react to the treatment. This includes checking things like liver function, as some medications can affect the liver. We'll also be studying how the body handles the drug – how much gets into the bloodstream, how quickly, and how long it stays there.
To ensure the results are as fair and accurate as possible, some participants will receive the new medicine and others will receive a 'placebo', which looks identical but contains no active drug. Neither the participants nor their study doctors will know who is getting which, until the study is over. This helps prevent any bias. By carefully collecting all this information, we hope to learn if VH4524184 could be a valuable new treatment option for people living with HIV.
Key takeaways
- This study is testing a new medicine (VH4524184) for people newly diagnosed with HIV-1 who haven't started treatment.
- It aims to see how well the drug reduces HIV levels and if it is safe.
- Participants will receive either the study drug or a placebo (dummy pill).
- Close monitoring of health, including liver function and side effects, will be performed.
- The study lasts about 10 days for treatment, with follow-up appointments afterward.
- Participation could help develop new HIV treatments.
Who may be eligible?
This study is open to adult men and women, aged 18 or older. To be part of this research, you must have HIV-1 but not have started any treatment for it yet. This is important because the study aims to see how the new medicine works in people who haven't been on other HIV medications.
There will also be other health checks to make sure the study medicine is safe for you. For example, your liver health will be carefully assessed. The study team will review your full medical history to confirm you meet all the necessary requirements for participation.
If you're interested, the study doctors and nurses will go through all the detailed criteria with you to determine if this study is a good fit for your current health situation.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have HIV-1?
- Have you *not* started any HIV treatment yet?
- Are you able to attend clinic visits regularly for about 10 days and follow-up?
- Are you willing to discuss your full medical history with the study team?
What does participation involve?
If you decide to take part in this study, you will be given either the new study medicine, VH4524184, or a dummy pill (placebo). Neither you nor your study doctor will know which you are receiving during the study. You will need to take this medication according to a specific schedule for about 10 days.
During this time, you will have several visits to the clinic. These visits are important for monitoring your health and how you react to the medication. This will involve blood tests to check your HIV levels, liver function, and to see how your body is handling the study drug. We'll also ask you about any side effects you might be experiencing.
After the 10-day treatment period, you will have follow-up appointments to continue monitoring your health. The total time you would be involved in the study, from your first visit to your last follow-up, will be explained in full by the study team.
Potential risks and benefits
Locations (2)
- —UnverifiedSpain
- —UnverifiedItaly
Common questions
What is HIV-1 RNA?
HIV-1 RNA is the genetic material of the HIV virus. Measuring it in your blood tells us how much of the virus is present, also known as your viral load.
What does 'treatment naïve' mean?
It means you have HIV but have not yet started any medication specifically to treat HIV.
What is a 'placebo'?
A placebo is a dummy pill that looks exactly like the study medicine but doesn't contain any active drug. It helps researchers compare the effects of the new medicine accurately.
What are 'Adverse Events (AEs)'?
Adverse Events are any unwanted medical problems that happen during a study, whether they are related to the study medicine or not. They are carefully recorded and monitored.
Why are liver tests important in this study?
Some medications can affect the liver, so we'll be regularly checking your liver health to make sure the study drug isn't causing any problems.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.